Investors searching for more reasons to be cautious about the health of the software sector just got a big one, as Salesforce Inc. cut its subscription-revenue outlook and discussed heavy scrutiny on ...

Supported Releases: These releases have been certified by Bloomberg’s Enterprise Products team for use by Bloomberg customers. Experimental Releases: These releases have not yet been certified for use ...

Anthropic’s Claude Tag works as a rival AI teammate inside Slack. Salesforce promoted it publicly, but employees worry it competes with their own Slackbot and Agentforce. When Anthropic launched ...

An attacker broke into competitive-intelligence vendor Klue, stole OAuth tokens its customers use to connect to Salesforce and other platforms, and accessed data across multiple customer environments ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

Who Is Salesforce CRM For? Salesforce is a powerhouse platform ideal for companies that want to see better results from their sales and marketing efforts. You can run multichannel campaigns through ...

I have a $386.80 intrinsic value for Salesforce. With the current price of $150.12, this represents a 158% upside. I believe CRM is getting thrown out with the proverbial bathwater due to the fear ...

2-Year U.S. Treasury Note Continuous Contract $103.027-0.012-0.01% 5-Year U.S. Treasury Note Continuous Contract $106.750 0.070 0.07% 10-Year U.S. Treasury Note Continuous Contract $109.297 0.156 0.14 ...

Salesforce is “likely to be negatively impacted by the advent of agentic AI,” one analyst said. He upgraded the stock anyway.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at ...

Sage CRM stands out as a dependable, feature-rich solution designed for small to medium-sized businesses that excels in providing a customizable platform that can scale with a company's growth.

China has such a dominant position in active pharmaceutical ingredient (API) production that there is a risk it could "weaponise" access, according to a new congressional report. The document, from ...